The global burden of neurodegenerative diseases is accelerating at an unprecedented rate, creating what public health experts describe as a “dementia epidemic” with profound implications for healthcare systems, families, and economies. Beyond Alzheimer’s, other neurodegenerative conditions including Parkinson’s disease, ALS and vascular dementia are following similar growth trajectories, collectively creating unprecedented pressure on neurological care resources and specialized facilities.

This mounting challenge is driving innovation across multiple fronts. Early detection capabilities are advancing through blood-based biomarkers, retinal imaging and digital cognitive assessments that can identify subtle changes years before clinical symptoms emerge. Meanwhile, the focus is expanding to include prevention, with mounting evidence suggesting that many dementia cases could be delayed or prevented through addressing modifiable risk factors.